Datapoint: Tivdak Scores FDA Nod for Cervical Cancer
The FDA on Sept. 20 granted an accelerated approval to Seagen Inc. and Genmab A/S’s Tivdak for the treatment of recurrent or metastatic cervical cancer that has continued to progress following chemotherapy. The drug is the first antibody-drug conjugate approved for cervical cancer. Among the most advantaged cervical cancer therapies are Roche’s Avastin, which holds covered or better status for 89% of all insured lives under the medical benefit, Amgen’s Mvasi (a biosimilar to Avastin, also 89%) and Merck’s Keytruda (85%).
SOURCE: MMIT Analytics, as of 9/23/21
© 2024 MMIT